Gendyne Therapeutics

Gendyne Therapeutics is a biotechnology company specializing in the development of targeted gene therapies for oncology. The company's core technology is a proprietary adenoviral vector platform that enables precise delivery of genetic payloads to cancer cells while minimizing off-target effects. Currently in the pre-clinical stage, Gendyne is advancing programs for solid tumors, with a primary focus on ovarian cancer. The company was founded based on research from Washington University in St. Louis and aims to redefine the therapeutic potential of viral vectors in cancer treatment. Their approach specifically addresses the challenge of liver sequestration, allowing for more effective systemic administration of viral therapies.